{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:56:53Z","timestamp":1782331013606,"version":"3.54.5"},"reference-count":46,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,22]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>VWF attenuates primed T-cell proliferation and memory B-cell differentiation. VWF mitigates FVIII memory responses in FVIIInull mice.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017009209","type":"journal-article","created":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T01:05:16Z","timestamp":1503104716000},"page":"1565-1574","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["The impact of von Willebrand factor on factor VIII memory immune responses"],"prefix":"10.1182","volume":"1","author":[{"given":"Juan","family":"Chen","sequence":"first","affiliation":[{"name":"Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn A.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI;"},{"name":"Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI;"},{"name":"Children\u2019s Research Institute, Children\u2019s Hospital of Wisconsin, Milwaukee, WI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Luo","sequence":"additional","affiliation":[{"name":"Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhen","family":"Shi","sequence":"additional","affiliation":[{"name":"Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI;"},{"name":"Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI;"},{"name":"Children\u2019s Research Institute, Children\u2019s Hospital of Wisconsin, Milwaukee, WI; and"},{"name":"MACC Fund Research Center, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,8,18]]},"reference":[{"issue":"4117","key":"2019111608353348500_B1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1126\/science.182.4117.1149","article-title":"Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity","volume":"182","author":"Weiss","year":"1973","journal-title":"Science"},{"key":"2019111608353348500_B2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.cb.06.110190.001245","article-title":"Cell biology of von Willebrand factor","volume":"6","author":"Wagner","year":"1990","journal-title":"Annu Rev Cell Biol"},{"issue":"32","key":"2019111608353348500_B3","doi-asserted-by":"crossref","first-page":"21948","DOI":"10.1016\/S0021-9258(18)54729-3","article-title":"The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII","volume":"266","author":"Wise","year":"1991","journal-title":"J Biol Chem"},{"issue":"2","key":"2019111608353348500_B4","first-page":"201","article-title":"Regulation of factor VIII expression and activity by von Willebrand factor","volume":"82","author":"Kaufman","year":"1999","journal-title":"Thromb Haemost"},{"issue":"18","key":"2019111608353348500_B5","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1182\/blood-2012-01-394411","article-title":"How we choose factor VIII to treat hemophilia","volume":"119","author":"Mannucci","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2019111608353348500_B6","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"issue":"suppl 6","key":"2019111608353348500_B7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2516.2006.01360.x","article-title":"Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors","volume":"12","author":"Astermark","year":"2006","journal-title":"Haemophilia"},{"issue":"6","key":"2019111608353348500_B8","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1172\/JCI118558","article-title":"Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A","volume":"97","author":"Gilles","year":"1996","journal-title":"J Clin Invest"},{"issue":"suppl 2","key":"2019111608353348500_B9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2516.2012.02797.x","article-title":"Management of bleeding disorders in adults","volume":"18","author":"Peyvandi","year":"2012","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"2019111608353348500_B10","first-page":"30","article-title":"Immune tolerance for the treatment of factor VIII inhibitors--twenty years\u2019 \u2018bonn protocol\u2019","volume":"70","author":"Brackmann","year":"1996","journal-title":"Vox Sang"},{"issue":"3","key":"2019111608353348500_B11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2516.1999.00311.x","article-title":"German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies","volume":"5","author":"Brackmann","year":"1999","journal-title":"Haemophilia"},{"issue":"5","key":"2019111608353348500_B12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2141.2010.08263.x","article-title":"Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches","volume":"150","author":"Coppola","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111608353348500_B13","article-title":"Epidemiology of inhibitors and current treatment strategies","author":"Kreuz","year":"2003"},{"issue":"23","key":"2019111608353348500_B14","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2019111608353348500_B15","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111608353348500_B16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2516.2007.01484.x","article-title":"Immune tolerance induction with a high purity von Willebrand factor\/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response","volume":"13","author":"Gringeri","year":"2007","journal-title":"Haemophilia"},{"issue":"4","key":"2019111608353348500_B17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/bjh.12942","article-title":"Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review","volume":"166","author":"van Velzen","year":"2014","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"2019111608353348500_B18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ijlh.12659","article-title":"Factor VIII inhibitors: advances in basic and translational science","volume":"39","author":"Lai","year":"2017","journal-title":"Int J Lab Hematol"},{"issue":"21","key":"2019111608353348500_B19","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111608353348500_B20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2006-05-022756","article-title":"VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors","volume":"109","author":"Dasgupta","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111608353348500_B21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0037-1613191","article-title":"Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model","volume":"88","author":"Behrmann","year":"2002","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111608353348500_B22","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood-2008-09-174649","article-title":"Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice","volume":"114","author":"Qadura","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111608353348500_B23","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1055\/s-0037-1613416","article-title":"A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions","volume":"89","author":"Reipert","year":"2003","journal-title":"Thromb Haemost"},{"issue":"7","key":"2019111608353348500_B24","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI28416","article-title":"Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies","volume":"116","author":"Shi","year":"2006","journal-title":"J Clin Invest"},{"issue":"16","key":"2019111608353348500_B25","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2010-03-272419","article-title":"Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A","volume":"116","author":"Shi","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111608353348500_B26","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1111\/j.1538-7836.2012.04902.x","article-title":"Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo","volume":"10","author":"Shi","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019111608353348500_B27","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/jth.13001","article-title":"The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies","volume":"13","author":"Shi","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111608353348500_B28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet"},{"issue":"3","key":"2019111608353348500_B29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood-2013-08-520478","article-title":"Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"key":"2019111608353348500_B30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1479-5876-10-30","article-title":"NOD\/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo","volume":"10","author":"Spranger","year":"2012","journal-title":"J Transl Med"},{"issue":"10","key":"2019111608353348500_B31","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2005-03-1182","article-title":"High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors","volume":"106","author":"Hausl","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2019111608353348500_B32","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/jth.12633","article-title":"In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection","volume":"12","author":"Schroeder","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019111608353348500_B33","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1182\/blood-2008-02-138214","article-title":"Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity","volume":"112","author":"Shi","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111608353348500_B34","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.4049\/jimmunol.163.6.3053","article-title":"Effector CD4 T cells are biochemically distinct from the memory subset: evidence for long-term persistence of effectors in vivo","volume":"163","author":"Ahmadzadeh","year":"1999","journal-title":"J Immunol"},{"issue":"4","key":"2019111608353348500_B35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1152\/advan.00066.2013","article-title":"T cell responses: naive to memory and everything in between","volume":"37","author":"Pennock","year":"2013","journal-title":"Adv Physiol Educ"},{"issue":"5770","key":"2019111608353348500_B36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1126\/science.1124228","article-title":"Naive and memory CD4+ T cell survival controlled by clonal abundance","volume":"312","author":"Hataye","year":"2006","journal-title":"Science"},{"issue":"11","key":"2019111608353348500_B37","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/eji.201343751","article-title":"The who\u2019s who of T-cell differentiation: human memory T-cell subsets","volume":"43","author":"Mahnke","year":"2013","journal-title":"Eur J Immunol"},{"issue":"2","key":"2019111608353348500_B38","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0037-1614450","article-title":"Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A","volume":"81","author":"Qian","year":"1999","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111608353348500_B39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.2830420408","article-title":"Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study","volume":"42","author":"Bray","year":"1993","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111608353348500_B40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2003-07-2456","article-title":"Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders","volume":"104","author":"Hausl","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2019111608353348500_B41","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/blood-2003-07-2207","article-title":"In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody","volume":"103","author":"Gilles","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111608353348500_B42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-0037-1612915","article-title":"Mechanism of the immune response to human factor VIII in murine hemophilia A","volume":"85","author":"Wu","year":"2001","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111608353348500_B43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J Leukoc Biol"},{"issue":"8","key":"2019111608353348500_B44","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/j.1538-7836.2012.04791.x","article-title":"Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity","volume":"10","author":"Kuether","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2019111608353348500_B45","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2015-08-662916","article-title":"The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity","volume":"127","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111608353348500_B46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/bloodadvances.2016001453","article-title":"TGF-\u03b21 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice","volume":"1","author":"Haribhai","year":"2016","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/19\/1565\/877983\/advances009209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/19\/1565\/877983\/advances009209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T04:30:03Z","timestamp":1692937803000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/19\/1565\/15699\/The-impact-of-von-Willebrand-factor-on-factor-VIII"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,18]]},"references-count":46,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2017,8,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017009209","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,18]]}}}